Treatment Options for ADHD

For patients with ADHD, FDA-approved stimulant medications—specifically methylphenidate or amphetamine-based agents—should be prescribed as first-line therapy, achieving 70-80% response rates with the largest effect sizes of any ADHD medication class. 1, 2

Treatment Algorithm by Age Group

Preschool-Aged Children (4-5 Years)

Start with evidence-based parent training in behavior management (PTBM) and/or behavioral classroom interventions as first-line treatment. 1
Methylphenidate may be considered as second-line pharmacological treatment if behavioral interventions fail to provide significant improvement and moderate-to-severe functional disturbance persists. 1, 2
Weigh the risks of starting medication before age 6 against the harm of delaying treatment when behavioral interventions are unavailable. 3

Elementary and Middle School-Aged Children (6-11 Years)

Prescribe FDA-approved stimulant medications (methylphenidate or amphetamines) along with PTBM and/or behavioral classroom interventions—preferably both. 1, 2
Stimulants demonstrate particularly strong evidence in this age group, with 70-80% response rates when properly titrated. 1, 2
Start with long-acting formulations (e.g., Concerta 18 mg once daily or mixed amphetamine salts XR 10 mg once daily) to improve adherence, provide consistent all-day coverage, reduce rebound effects, and lower diversion potential. 2, 3
Titrate methylphenidate by 18 mg weekly (maximum 54-72 mg daily) or amphetamines by 5-10 mg weekly (maximum 40 mg daily in children). 1, 2

Adolescents (12-17 Years)

Prescribe FDA-approved stimulant medications with the adolescent's assent, combined with behavioral interventions. 1
For adolescents, amphetamine-based stimulants (mixed amphetamine salts or lisdexamfetamine 20-30 mg starting dose, titrated to 50-70 mg) are preferred based on comparative efficacy studies. 2, 3
Long-acting formulations are especially important in adolescents due to lower diversion risk and improved adherence. 2, 3

Adults

Amphetamine-based stimulants are preferred for adults, with lisdexamfetamine or mixed amphetamine salts as first-line options. 2, 3
Start Adderall XR at 10 mg once daily in the morning, titrating by 5 mg weekly up to a maximum of 50 mg daily (typical therapeutic range 10-50 mg). 2, 3
Start lisdexamfetamine at 20-30 mg once daily, titrating by 10 mg weekly up to 70 mg maximum. 2, 3
Methylphenidate remains equally effective, dosed at 5-20 mg three times daily for immediate-release or using extended-release formulations for once-daily dosing (maximum 60 mg daily). 2, 3

Medication Selection and Dosing

First-Line Stimulants

Methylphenidate:

Initiate at 18 mg once daily (Concerta) or 5 mg three times daily (immediate-release). 1, 2
Increase by 18 mg weekly for extended-release or 5-10 mg weekly for immediate-release. 1, 2
Maximum dose: 54-72 mg daily (extended-release) or 60 mg daily (immediate-release). 1, 2
Approximately 40% of patients respond to both methylphenidate and amphetamines, while another 40% respond to only one class—trial both before declaring stimulant failure. 2, 3

Amphetamines:

Mixed amphetamine salts: Start 10 mg once daily (XR) or 5 mg twice daily (IR), titrate by 5-10 mg weekly to maximum 40-50 mg daily. 1, 2
Lisdexamfetamine: Start 20-30 mg once daily, titrate by 10 mg weekly to maximum 70 mg daily. 2, 3
Dextroamphetamine: Start 5 mg once daily, titrate by 2.5-5 mg weekly to 10-50 mg daily in divided doses. 2

Second-Line Non-Stimulants

Reserve non-stimulant medications for patients who have failed two or more stimulant trials, experience intolerable stimulant side effects, or have active substance-use disorders. 2, 4

Atomoxetine:

Target dose: 60-100 mg daily (maximum 1.4 mg/kg/day or 100 mg, whichever is lower). 2, 4
Start at 40 mg daily for adults (≥70 kg) or 0.5 mg/kg/day for children/adolescents (<70 kg). 4
Titrate after minimum 3 days to 80 mg daily (adults) or 1.2 mg/kg/day (children), with dose adjustments every 7-14 days. 4
Full therapeutic effect requires 6-12 weeks (median 3.7 weeks), significantly longer than stimulants which work within days. 2, 4
Effect size approximately 0.7 compared to stimulants (1.0). 2, 4
Provides 24-hour coverage with no abuse potential—ideal for substance-use concerns. 2, 4
FDA black-box warning for suicidal ideation requires close monitoring, especially during first few months or dose changes. 4

Extended-Release Guanfacine:

Start 1 mg once daily at bedtime, titrate by 1 mg weekly based on response. 2, 3
Target dose: 0.05-0.12 mg/kg/day (maximum 7 mg daily). 2
Effect size approximately 0.7, with full effect in 2-4 weeks. 2, 3
Particularly useful for comorbid sleep disturbances, tics, Tourette syndrome, or disruptive behavior disorders. 2, 3
Evening dosing preferred due to sedation. 2, 3
Never abruptly discontinue—taper by 1 mg every 3-7 days to avoid rebound hypertension. 2

Extended-Release Clonidine:

Similar dosing and effect size to guanfacine (approximately 0.7). 2, 3
Useful for same comorbidities as guanfacine. 2, 3
Must be tapered when discontinuing to prevent rebound hypertension. 2, 4

Comorbid Conditions and Treatment Modifications

ADHD with Anxiety or Depression

Start with stimulant monotherapy even when anxiety or depression is present, unless the mood disorder is severe (psychosis, suicidality, marked neurovegetative signs). 1, 2
Stimulants work within days, allowing rapid assessment of ADHD response and potentially indirect improvement of mood/anxiety by reducing functional impairment. 2
High-quality data from the MTA study show stimulants do not exacerbate anxiety and response rates were actually higher in the anxious subgroup. 2
If ADHD symptoms improve but mood/anxiety symptoms persist after 6-8 weeks of optimized stimulant dosing, add an SSRI (fluoxetine or sertraline) to the stimulant regimen. 1, 2
No single antidepressant effectively treats both ADHD and depression—sequential treatment is required. 2
SSRIs are weight-neutral with long-term use and can be safely combined with stimulants (no significant pharmacokinetic interactions). 2
For severe mood disorders with psychosis, suicidality, or pronounced neurovegetative signs, treat the mood disorder first before initiating ADHD medication. 2

ADHD with Bipolar Disorder

Mood stabilizers (lithium, valproate, or atypical antipsychotics) must be established and optimized before any stimulant is introduced. 2
Documented euthymia must be maintained for at least 2-4 weeks before initiating ADHD pharmacotherapy. 2
Mood stabilizers must be continued after ADHD medication is started—discontinuation removes protective effect against stimulant-induced mood destabilization. 2
A randomized controlled trial showed low-dose mixed amphetamine salts were safe and effective for comorbid ADHD only after mood symptoms were stabilized with divalproex. 2
The single most frequent error in practice is treating ADHD before the bipolar disorder is adequately stabilized. 2

ADHD with Autism Spectrum Disorder

Stimulants remain first-line, with methylphenidate and amphetamines achieving 70-80% response rates. 2, 3
Atomoxetine has demonstrated efficacy in children with ADHD and comorbid autism spectrum disorder and may be preferred as first-line in this population. 4, 5
Alpha-2 agonists (guanfacine or clonidine) are particularly useful when anxiety, agitation, or sleep problems coexist. 2, 3

ADHD with Substance Use Disorder

Prioritize non-stimulant medications (atomoxetine) as first-line therapy because active substance use shifts the treatment algorithm away from stimulants. 2, 4
If non-stimulants are inadequate, consider long-acting stimulant formulations with lower abuse potential (lisdexamfetamine or OROS-methylphenidate) only after addressing the underlying substance-use issue. 2, 3
Atomoxetine's lack of abuse potential eliminates risk of medication diversion. 2, 4
Daily stimulant treatment can reduce ADHD symptoms and risk for relapse to substance use in patients with comorbid substance dependence, with methylphenidate-treated groups showing significantly higher proportions of drug-negative urines. 3

ADHD with Tics or Tourette Syndrome

Atomoxetine does not exacerbate tics and may be preferred as first-line. 4
Alpha-2 agonists (guanfacine or clonidine) are FDA-approved and particularly helpful when tics coexist with ADHD. 2, 3
Stimulants can be used cautiously but require monitoring for tic exacerbation. 1

Monitoring Requirements

Baseline Assessment

Measure blood pressure and pulse. 1, 2
Obtain detailed cardiac history (syncope, chest pain, palpitations, exercise intolerance) and family history of premature cardiovascular death, arrhythmias, or structural heart disease. 2
Document all prior ADHD-related treatments (medications, doses, duration, response, side-effects, adherence). 2
Screen adolescents and adults for substance-use risk. 2
Screen for comorbid emotional, behavioral, developmental, and physical conditions. 1

During Titration (First 4-6 Weeks)

Measure blood pressure and pulse weekly. 1, 2
Obtain weekly ADHD symptom ratings from patient and informant. 2
Assess sleep quality and appetite changes. 1, 2
Monitor for suicidality, especially when using atomoxetine or SSRIs. 2, 4

Maintenance Phase

Check blood pressure and pulse quarterly in adults, at every visit in children/adolescents. 2
Measure height and weight at every visit in children/adolescents to monitor growth effects. 1, 2
Assess functional improvement across home, school/work, and social settings. 1, 2
Schedule monthly visits until stability is achieved, then quarterly. 2

Common Pitfalls and How to Avoid Them

Do not under-dose stimulants out of fear of side effects—systematic titration protocols enable roughly 70% of patients to achieve optimal response. 1, 2
Do not assume the first long-acting dose is sufficient—most patients require titration to doses higher than the summed short-acting dose. 2
Do not discontinue stimulants prematurely due to comorbid anxiety—evidence shows stimulants do not exacerbate anxiety and may yield higher response rates in anxious subgroups. 2
Do not base dosing on mg/kg calculations—systematic titration to the lowest effective dose that yields clinical benefit is preferred. 1, 2
Do not prescribe immediate-release methylphenidate for "as-needed" use—this approach lacks evidence and creates erratic symptom control. 3
Do not treat ADHD before bipolar disorder is adequately stabilized—this is the most frequent error in practice. 2
Do not assume a single antidepressant will effectively treat both ADHD and depression—no single antidepressant is proven for this dual purpose. 2
Do not delay ADHD treatment because of co-occurring mood symptoms—untreated ADHD worsens overall functional impairment and can exacerbate anxiety and depression. 2, 3

Special Populations

Pregnancy and Lactation

Current evidence shows no association between amphetamine or methylphenidate use and major congenital malformations. 2, 3
Modest increased risks of preeclampsia (adjusted relative risk 1.29) and preterm birth (aRR 1.30) have been reported when stimulants are continued in the second half of pregnancy. 2
Continuing stimulant therapy during pregnancy is advised when ADHD symptoms cause significant functional impairment, as abrupt discontinuation may worsen maternal mental health and adversely affect fetal development. 3
Amphetamines are classified as Hale lactation risk category L3 (probably compatible with breastfeeding but requiring infant monitoring). 2
In non-breastfeeding postpartum women, resumption of stimulants at the previous dose is appropriate, as maternal functional benefits outweigh potential risks. 2

Cardiovascular Concerns

Stimulants are contraindicated in symptomatic cardiovascular disease or uncontrolled hypertension. 1, 2
Methylphenidate has slightly lower cardiovascular effects than amphetamines, with average increases of 1-2 beats per minute for heart rate and 1-4 mm Hg for blood pressure. 3
Atomoxetine produces modest cardiovascular effects that are less pronounced than stimulants. 4
Extended-release guanfacine and clonidine actually decrease heart rate and blood pressure, making them uniquely beneficial for patients with cardiovascular concerns. 3
If any cardiac risk factors are present (family history of sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome), obtain ECG and consider cardiology referral before starting treatment. 2, 3

What are the recommended treatment options for a patient with ADHD, including medication choices and dosing based on age and comorbid conditions?

Help us tailor your experience